GW Pharmaceuticals and its U.S. Subsidiary Greenwich Biosciences Completes Rolling NDA Submission to U.S. FDA for Epidiolex (cannabidiol) in the Treatment of Lennox-Gastaut Syndrome and Dravet Syndrome

LONDON and CARLSBAD, Calif., Oct. 30, 2017 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) ( " GW " or " the Company " ), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news